newsfilter
← Latest News
GlobeNewswire·

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1